Shenping Medical, Baifu Laser, Yingfumei and Other High-Tech Firms Announce Financing Plans on VB Insights' Supply-Demand Matching Platform

As of now, VCBeat has launched the link.Nearly 1,000 items, average clicks per link50+, Maximum Successful Connections per Single Line>10 times。

Continued Release of Preferred Series Partnership Links, This Issue’s Special Topic: “Financing”. According to statistics, a total of in the domestic medical and health sector in the first half of 2024696 casesInvestment and financing events (excluding M&A, private placements, and equity transfers) increased by 2.20% compared to 681 cases in the same period of 2023 (data source: Yuanshi Capital). Currently, the pharmaceutical industry is developing steadily, driven by multiple factors including innovation-driven growth, international expansion, national policy support, technological advancements, and consumption upgrades. Several medical technology companies have announced financing and cooperation plans. Details are as follows:

● Collaboration Requirements:

1. Development Plan:

1) Wuhan: R&D + Pilot Scale-up

3,000㎡ R&D Center + 5,000㎡ Pilot-Scale Base

Jianghan University’s Science and Technology Innovation Center has allocated an entire floor, totaling 1,500 square meters, for the establishment of the Wuhan Yuanqi Application Development Center, with occupancy expected in October 2024.

5,000 m² Production Base to Begin Construction in Q3; Phase I Capacity of 10 Tons

2) Beijing—Global Operations Center

2. Financing Planning:

1) RMB 30 million—This funding round raises RMB 30 million in exchange for a 20% equity stake in Wuhan Yuanqi, resulting in a post-money valuation of RMB 150 million.

2) Usage Plan – 20% for product development and qualification filing, 30% for sales operations, and 50% for clinical trial application of hirudin

●Company/Product Introduction：

The company is positioned to establish a high-end domestic brand in the field of medical aesthetic optoelectronics. As upstream products in the medical and beauty industry chain, laser medical devices will continue to benefit from overall industry growth, presenting substantial market potential. Baifu Group is a high-tech enterprise focused on the high-end laser medical aesthetics sector, with digital and intelligent medical solutions at its core. At present, the company is dedicated to the independent research and development, manufacturing, sales, and scientific research services of innovative products in dermatology, plastic surgery, rehabilitation medicine, and the broader health industry. Some of its equipment has already achieved breakthroughs in domestic production. The company has independently developed a series of laser products, including ND:YAG Q-switched lasers, 1064 nm long-pulse lasers, 755 nm alexandrite long-pulse lasers, 2940 nm erbium lasers, and 1064/532 nm picosecond lasers, with relevant technical indicators reaching a leading level in China. Its products have obtained CE, FDA, and NMPA certifications and are exported to more than 60 countries and regions.

●Collaboration Requirements:

Baifu Laser has launched its Series B+ financing round, with the fundraising amount capped at RMB 50 million.

●Company/Product Introduction：

Meishangjie Biotechnology Co., Ltd. has achieved significant accomplishments in the field of gene editing, driven by its forward-looking R&D philosophy and leading technological prowess. The company’s proprietary recombinant gene editing technology ingeniously combines recombinant collagen with recombinant fibronectin to create a unique microcapsule structure. This technology not only preserves the biological activity of collagen but also enhances its permeability and stability within the skin. Meishangjie has further developed this innovation into a comprehensive technological platform with the potential to engineer proteins tailored for various parts of the human body.

Currently, the company has successfully developed recombinant human BMP-2 protein, recombinant human GDF-11/BMP-11 protein, and recombinant metallothionein. These recombinant proteins hold broad application prospects and potential value in the fields of medicine and biotechnology.

●Collaboration Requirements:

In the first half of 2024, Jiangsu Meishangjie Biotechnology Co., Ltd. successfully secured tens of millions of RMB in Series A financing. The round was led by Shanghai Jiushong Shanhe Investment, with participation from Zhangjiagang Jinxin Capital and Zhangjiagang City Fund’s Zhangchuangtou.

To further increase investment in R&D and market expansion, continuously enhance the core competitiveness of its products, and expand market share, a new round of financing has been launched, with Xuyi Capital serving as the financial advisor.

●Company/Product Introduction：

Xingming Youjian is an ophthalmic drug company incubated by Fuxian Capital, the innovation fund of Fuxian New Drug. The company focuses on the development of in vivo gene therapy products for ophthalmic diseases, targeting photoreceptor degenerative diseases and optic nerve degenerative diseases., leveraging proprietary optogenetics and in situ transdifferentiation technologies to independently develop optogenetic and optic nerve regeneration AAV gene therapy products.

Over the past three years since its establishment, Xingming Youjian has confirmed lightTwo technological approaches, genetics and neural regeneration, underpin three pipelines in development. The most advanced pipeline has progressed to investigator-initiated trials (IITs), with partial interim results disclosed, demonstrating excellent safety and efficacy.

●Collaboration Requirements:

The company is currently launching a new round of financing.

●Corporate/Product Introduction：

Chengdu Feiming Technology Co., Ltd., established in November 2017, is a wholly-owned subsidiary of Quark Pharma (China) Co., Ltd. As an innovative medical device R&D company, Feiming Technology leverages computer technologies such as virtual reality, computer vision, and big data to develop multiple models of medical devices for "musculoskeletal rehabilitation and neurological rehabilitation."Rehabilitation medical devices are dedicated to helping patients achieve clinical goals in motor impairment rehabilitation through human-machine intelligence and the integration of physical exercise with medicine. Currently, multiple medical device R&D projects are underway.

Virtual Reality Intelligent Rehabilitation Medical Devices Are Primarily Designed forThe company targets two markets: hospital-specific and general home use. It plans to first establish its presence in the hospital-specific market, then gradually expand into the home-use sector through hospitals and physicians.

●Collaboration Requirements:

The proceeds from this financing round will be allocated to the R&D of the stroke pipeline, market expansion for regulatory registration and product sales, development of new pipelines, and the introduction of new technologies.

●Company/Product Introduction：

The company specializes in the fields of neurosurgery and interventional procedures, dedicated to enhancing the precision and standardization of clinical surgeries while reducing operational risks. The management team boasts over 10 years of experience in the neuroscience industry, and the core R&D team possesses comprehensive experience in the full-cycle development of medical device products. The company holds more than 70 patent applications.

The company’s competitive differentiation lies in achieving low-cost domestic substitution through technological innovation, with pricing at one-sixth that of comparable competitors.

●Cooperation Requirements:

The company is currently seeking financing; interested investment institutions are welcome to contact us for further discussion.

●Corporate/Product Introduction：

Yingfumei focuses on the specialized vertical field of comprehensive kidney diseases, aiming to build a 360° all-encompassing data management platform. In addition to the electronic medical record (EMR) system for hemodialysis, the company has concurrently developed EMR systems for peritoneal dialysis and continuous renal replacement therapy (CRRT). Together, these three systems constitute the i-DiaPro Integrated Data Management Platform for Blood Purification. The company has also developed China’s first follow-up app for kidney disease, “Yaoguo Doctor,” which serves as a doctor-patient communication platform bridging out-of-hospital and in-hospital care. The app integrates a nephrology drug dictionary, containing medication information related to kidney diseases and covering all common chronic conditions and various types of renalinflammation, syndromes, renal failure, and other specialized knowledge; on the platform, physicians can conduct follow-up assessments of patients anytime and anywhere, freely customize questionnaire templates suitable for all types of chronic kidney disease, perform data entry through selection, identify laboratory test results, and easily complete follow-up.follow-up work, while the system itself can also perform multi-dimensional statistical analysis of data to support scientific research and policy formulation.

●Cooperation Requirements:

Industry’s First Class III Registered Innovative Medical Device Software for AI-Powered, Non-Invasive, Real-Time Assessment of Biochemical Indicators in Blood Purification: Seeking Market Partnerships and Series B Financing.

●Company/Product Introduction：

Antis’s rhythmically targeted, low-intensity transcranial magnetic stimulation technology capable of reaching deep brain regions (abbreviated as rDMS) holds global patents. Product development has been completed, and the company has long collaborated with numerous experts and scholars in the fields of neuroscience and brain disorders both domestically and internationally.Collaboration has completed extensive basic and clinical research, with findings supporting the immediate initiation of medical device registration clinical trials.Effective prevention and treatment of insomnia, depression, and AD.

Antis will contribute mainstream intervention methods originating from China to the prevention and treatment of major human brain diseases.

●Cooperation Requirements:

Pre-Series A: RMB 30 million

Series A: $15 million

●Corporate/Product Introduction：

Project Progress: The software and hardware development for the supply chain management system of private dental clinics has been completed, securing 9 patents (including 2 invention patents) and 10 software copyrights. The supply chain procurement platform is currently under construction. To date, the system has been installed in 10 clinics, with nearly 100 additional installation orders pending. Funding is required to procure hardware for the production and installation of equipment at these clinics. It is estimated that each clinic will generate annual consumables sales exceeding RMB 200,000.

Project Features: Leveraging advanced IoT technology, the solution enables end-to-end digital real-time tracking of clinic consumables—from scheduled procurement and delivery to warehouse management. This approach mitigates negative impacts stemming from manual management inefficiencies, such as overprocurement, operational disarray, material loss, poor supplier management, and expiration of supplies. It truly facilitates the digital and intelligent transformation of private clinics, enabling refined operational management.

Technical Highlights:Utilizing SaaS platform technology to reduce clinic operating costs and enable unified management across multiple locations; employing the most advanced IoT technology,Enables full lifecycle traceability management of medical consumables, facilitating inspections by drug regulatory authorities; employs AI-powered image recognition technology for intelligent reading of inbound and outbound documents, truly achieving paperless and convenient operations.

●Collaboration Requirements:

Seeking Pre-A round financing of 5 million

- VCBeat Supply and Demand Matching Platform covers: overseas expansion, supply chain, marketing/channels, technology transfer, and investment promotion/onboarding.

- Upload supply or demand resources on the platform to precisely reach target prospective partners

- Efficiently engage with entities such as multinational corporations (MNCs), startups, government industrial parks, and investment institutions